Logo image of GLSI

GREENWICH LIFESCIENCES INC (GLSI) Stock Overview

USA - NASDAQ:GLSI - US3968791083 - Common Stock

9.49 USD
-0.23 (-2.37%)
Last: 10/17/2025, 8:16:53 PM
9.85 USD
+0.36 (+3.79%)
After Hours: 10/17/2025, 8:16:53 PM

GLSI Key Statistics, Chart & Performance

Key Statistics
52 Week High15.47
52 Week Low8.06
Market Cap129.35M
Shares13.63M
Float6.37M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.36
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12
IPO09-25 2020-09-25
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


GLSI short term performance overview.The bars show the price performance of GLSI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10 -15

GLSI long term performance overview.The bars show the price performance of GLSI in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 -20

The current stock price of GLSI is 9.49 USD. In the past month the price decreased by -17.19%. In the past year, price decreased by -29.86%.

GREENWICH LIFESCIENCES INC / GLSI Daily stock chart

GLSI Latest News, Press Relases and Analysis

GLSI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.68 405.55B
AMGN AMGEN INC 13.7 160.87B
GILD GILEAD SCIENCES INC 15.87 152.38B
VRTX VERTEX PHARMACEUTICALS INC 24.61 106.87B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 63.14B
REGN REGENERON PHARMACEUTICALS 12.67 61.27B
ARGX ARGENX SE - ADR 91.01 51.63B
INSM INSMED INC N/A 35.04B
ONC BEONE MEDICINES LTD-ADR 5.11 34.76B
BNTX BIONTECH SE-ADR N/A 25.28B
NTRA NATERA INC N/A 24.94B
BIIB BIOGEN INC 8.93 20.97B

About GLSI

Company Profile

GLSI logo image Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 4 full-time employees. The company went IPO on 2020-09-25. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. The company has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.

Company Info

GREENWICH LIFESCIENCES INC

3992 Bluebonnet Dr, Building 14

Stafford Texas TEXAS 33954 US

CEO: Snehal Patel

Employees: 4

GLSI Company Website

GLSI Investor Relations

Phone: 12034343290

GREENWICH LIFESCIENCES INC / GLSI FAQ

What is the stock price of GREENWICH LIFESCIENCES INC today?

The current stock price of GLSI is 9.49 USD. The price decreased by -2.37% in the last trading session.


What is the ticker symbol for GREENWICH LIFESCIENCES INC stock?

The exchange symbol of GREENWICH LIFESCIENCES INC is GLSI and it is listed on the Nasdaq exchange.


On which exchange is GLSI stock listed?

GLSI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GREENWICH LIFESCIENCES INC stock?

8 analysts have analysed GLSI and the average price target is 42.84 USD. This implies a price increase of 351.42% is expected in the next year compared to the current price of 9.49. Check the GREENWICH LIFESCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GREENWICH LIFESCIENCES INC worth?

GREENWICH LIFESCIENCES INC (GLSI) has a market capitalization of 129.35M USD. This makes GLSI a Micro Cap stock.


How many employees does GREENWICH LIFESCIENCES INC have?

GREENWICH LIFESCIENCES INC (GLSI) currently has 4 employees.


What are the support and resistance levels for GREENWICH LIFESCIENCES INC (GLSI) stock?

GREENWICH LIFESCIENCES INC (GLSI) has a support level at 9.01 and a resistance level at 10.53. Check the full technical report for a detailed analysis of GLSI support and resistance levels.


Should I buy GREENWICH LIFESCIENCES INC (GLSI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GREENWICH LIFESCIENCES INC (GLSI) stock pay dividends?

GLSI does not pay a dividend.


When does GREENWICH LIFESCIENCES INC (GLSI) report earnings?

GREENWICH LIFESCIENCES INC (GLSI) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of GREENWICH LIFESCIENCES INC (GLSI)?

GREENWICH LIFESCIENCES INC (GLSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).


What is the Short Interest ratio of GREENWICH LIFESCIENCES INC (GLSI) stock?

The outstanding short interest for GREENWICH LIFESCIENCES INC (GLSI) is 19.38% of its float. Check the ownership tab for more information on the GLSI short interest.


GLSI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GLSI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to GLSI. GLSI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GLSI Financial Highlights

Over the last trailing twelve months GLSI reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by -70.79% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -575.74%
ROE -1249.92%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-50%
Sales Q2Q%N/A
EPS 1Y (TTM)-70.79%
Revenue 1Y (TTM)N/A

GLSI Forecast & Estimates

8 analysts have analysed GLSI and the average price target is 42.84 USD. This implies a price increase of 351.42% is expected in the next year compared to the current price of 9.49.


Analysts
Analysts82.5
Price Target42.84 (351.42%)
EPS Next Y6.93%
Revenue Next YearN/A

GLSI Ownership

Ownership
Inst Owners10.45%
Ins Owners53.23%
Short Float %19.38%
Short Ratio19.38